alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE>  5

<S>                           <C>
<PERIOD-TYPE>                 3-MOS
<FISCAL-YEAR-END>             OCT-31-2001
<PERIOD-START>                NOV-1-2000
<PERIOD-END>                  JAN-31-2001
<CASH>                        7,751,478
<SECURITIES>                  0
<RECEIVABLES>                 38,633
<ALLOWANCES>                  (12,268)
<INVENTORY>                   2,073,207
<CURRENT-ASSETS>              0
<PP&E>                        0
<DEPRECIATION>                0
<TOTAL-ASSETS>                9,851,050
<CURRENT-LIABILITIES>         0
<BONDS>                       1,337,870
<COMMON>                      0
<PREFERRED-MANDATORY>         0
<PREFERRED>                   0
<OTHER-SE>                    0
<TOTAL-LIABILITY-AND-EQUITY>  3,325,573
<SALES>                       0
<TOTAL-REVENUES>              0
<CGS>                         0
<TOTAL-COSTS>                 0
<OTHER-EXPENSES>              0
<LOSS-PROVISION>              0
<INTEREST-EXPENSE>            0
<INCOME-PRETAX>               0
<INCOME-TAX>                  0
<INCOME-CONTINUING>           0
<DISCONTINUED>                0
<EXTRAORDINARY>               0
<CHANGES>                     0
<NET-INCOME>                  0
<EPS-BASIC>                 0
<EPS-DILUTED>                 0


</TABLE>
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr.,

 Chief Justice

Michael F. Cavanagh

Marilyn Kelly

Stephen J. Markman

Diane M. Hathaway

Mary Beth Kelly

Brian K. Zahra, Justices

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

 _________________________________________ 

 Clerk

June 28, 2011 

y0620 

Order 

 

June 28, 2011 

142635 

PEOPLE OF THE STATE OF MICHIGAN, 

Plaintiff-Appellee, 

v SC: 142635 

 COA: 300557 

Ingham CC: 09-000215-FC 

TYRON BERNARD DAVIS, 

Defendant-Appellant. 

_________________________________________/ 

On order of the Court, the application for leave to appeal the January 3, 2011 order 

of the Court of Appeals is considered, and it is DENIED, because we are not persuaded 

that the questions presented should be reviewed by this Court.
# C_2023121EN.01001201.xml

| 3.4.2023 | EN | Official Journal of the European Union | C 121/12 |
| --- | --- | --- | --- |

3.4.2023

EN

Official Journal of the European Union

C 121/12

---

Action brought on 15 February 2023 — Oriflame Cosmetics v EUIPO — Caramé Holding (Representation of a stylised O)

(Case T-74/23)

(2023/C 121/16)

Language in which the application was lodged: English

Parties

Applicant: Oriflame Cosmetics AG (Schaffhausen, Switzerland) (represented by: N. Gerling and U. Pfleghar, lawyers)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Caramé Holding AG (Sulzbach, Germany)

Details of the proceedings before EUIPO

Proprietor of the trade mark at issue: Other party to the proceedings before the Board of Appeal

Trade mark at issue: International registration designating the European Union in respect of a figurative mark (Representation of a stylised O) — International registration designating the European Union No 1 303 496

Procedure before EUIPO: Opposition proceedings

Contested decision: Decision of the Second Board of Appeal of EUIPO of 7 December 2022 in Case R 938/2022-2

Form of order sought

The applicant claims that the Court should:

| — | annul the contested decision and the decision of the Opposition Division of EUIPO of 4 April 2022 and refuse international registration designating the European Union No 1 303 496; |
| --- | --- |

—

annul the contested decision and the decision of the Opposition Division of EUIPO of 4 April 2022 and refuse international registration designating the European Union No 1 303 496;

| — | Order EUIPO and the intervener to pay the costs incurred by the applicant in addition to bearing their own costs. |
| --- | --- |

—

Order EUIPO and the intervener to pay the costs incurred by the applicant in addition to bearing their own costs.

Pleas in law

| — | Infringement of Article 47(2) and (3) of Regulation (EU) 2007/1001 of the European Parliament and of the Council; |
| --- | --- |

—

Infringement of Article 47(2) and (3) of Regulation (EU) 2007/1001 of the European Parliament and of the Council;

| — | Infringement of Article 10(2) of Commission Delegated Regulation (EU) 2018/625. |
| --- | --- |

—

Infringement of Article 10(2) of Commission Delegated Regulation (EU) 2018/625.

---
Exhibit 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the Annual report of IGIA, Inc. (the "Company") on
Form 10-KSB for the period ending February 28, 2006 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Kurt Streams,
Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section
906 of the Sarbanes-Oxley Act of 2002, that:

         (3)      The Report fully complies with the requirements of section
                  13(a) or 15(d) of the Securities and Exchange Act of 1934; and

         (4)      The information contained in the Report fairly presents, in
                  all material respects, the financial condition and result of
                  operations of the Company.



Date:  June 13, 2006                     By:    /s/ Kurt Streams
                                                -----------------
                                                Kurt Streams
                                                Chief Financial Officer
<PAGE>
EXHIBIT 99.1

                    CERTIFICATION OF CEO AND CFO PURSUANT TO
                 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form[10-Q of Universal Automotive
Industries, Inc. (the "Company") for the quarterly period ended September 30,
2002 as filed with the Securities and Exchange Commission on the date hereof
(the "Report"), Arvin Scott, as Chief Executive Officer of the Company, Robert
W. Zimmer, as Chief Financial Officer of the Company, and Peter Riofski, as
Chief Accounting Officer of the Company, each hereby certifies, pursuant to 18
U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of
2002, that, to the best of his knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.

/s/ Arvin Scott
---------------

Name:  Arvin Scott

Title:  Chief Executive Officer
Date:  May 20, 2003

/s/ Robert W. Zimmer
--------------------

Name: Robert W. Zimmer
Title:  Chief Financial Officer
Date:  May 20, 2003

/s/ Peter Riofski
-----------------

Name:  Peter Riofski
Title:  Vice President & Controller
Date:  May 20, 2003

This certification accompanies the Report pursuant to ss. 906 of the
Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the
Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of ss.18
of the Securities Exchange Act of 1934, as amended.

See also the certification pursuant to Sec. 302 of the Sarbanes-Oxley Act of
2002, which is also attached to this Report.
STATE of North Carolina v. Shawntae Deshawn ROGERS, Defendant.

No. COA15-642.

Court of Appeals of North Carolina.

Feb. 2, 2016.

**Case Reported Without Published Opinion**

Vacated.
<TABLE> <S> <C>

<ARTICLE> 5

<S>                              <C>
<PERIOD-TYPE>                    3-MOS
<FISCAL-YEAR-END>                OCT-31-2001
<PERIOD-START>                   NOV-1-2000
<PERIOD-END>                     JAN-31-2001
<CASH>                           7,747,714
<SECURITIES>                     0
<RECEIVABLES>                    38,633
<ALLOWANCES>                     (12,268)
<INVENTORY>                      2,073,207
<CURRENT-ASSETS>                 0
<PP&E>                           0
<DEPRECIATION>                   0
<TOTAL-ASSETS>                   9,847,286
<CURRENT-LIABILITIES>            0
<BONDS>                          7,868,573
<COMMON>                         0
<PREFERRED-MANDATORY>            0
<PREFERRED>                      0
<OTHER-SE>                       0
<TOTAL-LIABILITY-AND-EQUITY>     9,847,268
<SALES>                          0
<TOTAL-REVENUES>                 0
<CGS>                            0
<TOTAL-COSTS>                    0
<OTHER-EXPENSES>                 0
<LOSS-PROVISION>                 0
<INTEREST-EXPENSE>               0
<INCOME-PRETAX>                  0
<INCOME-TAX>                     0
<INCOME-CONTINUING>              0
<DISCONTINUED>                   0
<EXTRAORDINARY>                  0
<CHANGES>                        0
<NET-INCOME>                     0
<EPS-BASIC>                    0
<EPS-DILUTED>                    0


</TABLE>
Exhibit 99.15

CONSENT OF LUC JONCAS

Reference is made to the Annual Report on Form 40-F and the documents incorporated by reference therein (the 40-F) of Goldcorp
Inc. (the Company) for the fiscal year ended December 31, 2013, and any amendments thereto, to be filed with the United States Securities and Exchange Commission pursuant to the United States Securities Exchange Act of 1934, as
amended, and the Annual Information Form (the AIF) and Managements Discussion and Analysis (MD&A) of the Company for the year then ended, which are filed as exhibits to and incorporated by reference in the 40-F.

I hereby consent to the references to, and the information derived from, the following report(s) and to the references, as applicable, to
my name in connection with (including, as an expert or qualified person) the following report(s) and/or documents:



|1. | The technical report that has an effective date of January 26, 2014, entitled Éléonore Gold Project Québec, Canada, NI 43-101 Technical Report (the Éléonore
Report); and
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|2. | The 40-F, the MD&A and the AIF, which include references in connection with information relating to the Éléonore Report and the Éléonore Project, and the properties described therein.
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

I also hereby consent to the incorporation by reference of such information contained in the 40-F, the MD&A and the AIF
into Registration Statement Nos. 333-126038, 333-126039, 333-126040, 333-151243, 333-151251, 333-174376, 333-181116 and 333-188805 on Form S-8 of the Company.

Date: March 31, 2014



/s/ Luc JoncasName: Luc Joncas, P.Eng.
STATE of North Carolina v. Corey Demond PHILLIPS, Defendant.

No. COA15-730.

Court of Appeals of North Carolina.

Feb. 16, 2016.

**Case Reported Without Published Opinion**

No Error.
Addendum to Agreement between Accentia and Baxter Healthcare Corp



 Exhibit 10.2 
 ADDENDUM TO AGREEMENT BETWEEN BAXTER HEALTHCARE CORPORATION 
 AND ACCENTIA
BIOPHARMACEUTICALS, INC. 
 This Addendum to the above-referenced Agreement is executed as of November 29, 2010 by the parties hereto to
clarify and affirm the Agreement as follows: 
 Notwithstanding anything to the contrary contained in the Agreement, the term “Effective
Date” shall be deemed to mean November 29, 2010. This definition of Effective Date shall control and supersede any conflicting or contradictory language in the Agreement, including without limitation Section 13.14, and the parties
agree and acknowledge that the Agreement is not and has not been rendered null and void pursuant to Section 13.14. 
 IN WITNESS WHEREOF, the Parties have caused this Addendum to Agreement to be executed as of this 29th day of November, 2010. 
  

									
	BAXTER HEALTHCARE CORPORATION	 		 	ACCENTIA BIOPHARMACEUTICALS, INC.
					
	By:	 	 /s/ Scott P. Luce
	 		 	By:	 	 /s/ Samuel S. Duffey

					
	Name:	 	 /s/ Scott P. Luce
	 		 	Name:	 	 Samuel S. Duffey

					
	Title:	 	 General Manager, Global Pharmaceuticals
	 		 	Title:	 	 President and General Counsel
May 15, 2012

JUDGMENT

The Fourteenth Court of Appeals

EX PARTE NANCY RICHEY

NO. 14-12-00253-CR

____________________

This cause was heard on the motion of the appellant to withdraw the notice of 

appeal. Having considered the motion, the Court orders the appeal DISMISSED and that 

the appellant pay all costs expended in this appeal, and further orders this decision 

certified below for observance.

We further order the Clerk of this Court to issue the mandate immediately.
In the Matter of K.H.

No. COA15-628.

Court of Appeals of North Carolina.

Nov. 17, 2015.

**Case Reported Without Published Opinion**

Affirmed.
STATE v. LOPEZ

No. COA07-986

Court of Appeals of North Carolina.

Filed February 19, 2008.

Certification Date March 10, 2008.

Appeal from Guilford (03CRS47920, 03CRS47921).

Decision without published opinion. No error in part; Vacated in part.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Defense

###### Department of the Navy 

# AGENCY:

Department of the Navy, DOD. 

# ACTION:

Notice of open meeting. 

# SUMMARY:

The Secretary of the Navy's Advisory Subcommittee on Naval History, a subcommittee of the Department of Defense Historical Advisory Committee will meet to review naval historical activities since the last meeting of the Advisory Subcommittee on Naval History, which was conducted on April 29, and April 30, 2004 and to make comments and recommendations on these activities to the Secretary of the Navy. The meetings will be open to the public. 

# DATES:

The meetings will be held on Thursday, September 29, 2005, from 8 a.m. to 4 p.m. and Friday, September 30, 2005, from 8 a.m. to 4 p.m. 

# ADDRESSES:

The meetings will be held at the Navy Museum of The Naval Historical Center, 805 Kidder Breese Street, SE., Building 76, Washington Navy Yard, DC, 20374-5060. 

# FOR FURTHER INFORMATION CONTACT:

Rear Admiral Paul E. Tobin, USN (Ret.), Director of Naval History, 805 Kidder Breese Street, SE., Bldg. 57, Washington Navy Yard, DC 20374-5060, telephone 202-433-2210. 

# SUPPLEMENTARY INFORMATION:

This notice of open meeting is provided in accordance with the Federal Advisory Committee Act (5 U.S.C. App. 2). The purpose of these meetings is to review naval historical activities since the last meeting of the Advisory Subcommittee on Naval History and to make comments and recommendations on these activities to the Secretary of the Navy. 

      ( print page 54908)    
Dated: September 12, 2005. 

I.C. Le Moyne Jr., 

Lieutenant, Judge Advocate General's Corps, U.S. Navy, Alternate Federal Register Liaison Officer. 

[FR Doc. 05-18538 Filed 9-16-05; 8:45 am] 

BILLING CODE 3810-FF-P
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### National Aeronautics and Space Administration

          - [Notice (05-139)] 

# AGENCY:

National Aeronautics and Space Administration. 

# ACTION:

Notice of availability of inventions for licensing. 

# SUMMARY:

The inventions listed below assigned to the National Aeronautics and Space Administration, have been filed in the United States Patent and Trademark office, and are available for licensing. 

# DATES:

September 16, 2005. 

# FOR FURTHER INFORMATION CONTACT:

David Walker, Patent Counsel, Goddard Space Flight Center, Mail Code 140.1, Greenbelt, MD 20771-0001; telephone (301) 286-7351; fax (301) 286-9502. 

NASA Case No. GSC-14561-1: Screw Locking Wrench; 

NASA Case No. GSC-14657-1: Evolvable Synthetic Neural System; 

NASA Case No. GSC-14762-1: Reconfigurable Structure; 

NASA Case No. GSC-14603-1: Anti-Backlash Gear-Bearings; 

NASA Case No. GSC-15002-1: Method And Associated Apparatus For Capturing, Servicing, And De-Orbiting Earth Satellites Using Robotics; 

NASA Case No. GSC-14525-2: Passive Gas-Gap Heat Switch For Adiabatic Demagnetization Refrigerator; 

NASA Case No. GSC-14648-1: Charge Dissipative Electrical Interconnect. 

Dated: September 12, 2005. 

Keith T. Sefton, 

Deputy General Counsel, Administration and Management. 

[FR Doc. 05-18449 Filed 9-15-05; 8:45 am] 

BILLING CODE 7510-13-P
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 08-1369

ROBERT R. CURTIS,

Plaintiff - Appellant,

v.

UNITED STATES OF AMERICA,

Movant - Appellee, 

and

JOHN O. THOMPSON; STEWART REMER; HELEN HURCOMBE; MARK LANGSTEIN;

JOHN MCNULTY,

Defendants.

Appeal from the United States District Court for the District of

Maryland, at Greenbelt. Roger W. Titus, District Judge. (8:05-cv00868-RWT)

Submitted: August 14, 2008 Decided: August 19, 2008

Before MICHAEL, Circuit Judge, and WILKINS and HAMILTON, Senior

Circuit Judges.

Affirmed by unpublished per curiam opinion.

Robert R. Curtis, Appellant Pro Se. Tarra R. DeShields-Minnis,

Assistant United States Attorney, Baltimore, Maryland, for

Appellee.
2

Unpublished opinions are not binding precedent in this circuit.
3

PER CURIAM:

Robert R. Curtis appeals the district court’s order

substituting the United States for all defendants and granting

judgment to the United States. We have reviewed the record and

find no reversible error. Accordingly, we affirm for the reasons

stated by the district court. See Curtis v. Thompson, No. 8:05-cv00868-RWT (D. Md. Jan. 31, 2008). We dispense with oral argument

because the facts and legal contentions are adequately presented in

the materials before the court and argument would not aid the

decisional process.

AFFIRMED
<TABLE> <S> <C>


<ARTICLE>                       5
<CIK>                           0000919550
<NAME>                          Nimbus CD International, Inc.
       
<S>                             <C>
<PERIOD-TYPE>                   12-mos
<FISCAL-YEAR-END>               Mar-31-1997
<PERIOD-END>                    Mar-31-1997 
<CASH>                          7,790
<SECURITIES>                        0
<RECEIVABLES>                  28,205
<ALLOWANCES>                    1,812
<INVENTORY>                     2,217
<CURRENT-ASSETS>               41,144
<PP&E>                         89,766
<DEPRECIATION>                 26,335
<TOTAL-ASSETS>                108,272
<CURRENT-LIABILITIES>          30,974
<BONDS>                             0
<PREFERRED-MANDATORY>               0
<PREFERRED>                         0
<COMMON>                          390
<OTHER-SE>                     52,032
<TOTAL-LIABILITY-AND-EQUITY>  108,272
<SALES>                       129,470
<TOTAL-REVENUES>              129,470
<CGS>                          91,961
<TOTAL-COSTS>                  91,961
<OTHER-EXPENSES>               21,477
<LOSS-PROVISION>                1,031
<INTEREST-EXPENSE>              2,666
<INCOME-PRETAX>                13,761
<INCOME-TAX>                    4,586
<INCOME-CONTINUING>             9,175
<DISCONTINUED>                      0
<EXTRAORDINARY>                     0
<CHANGES>                           0
<NET-INCOME>                    9,175
<EPS-PRIMARY>                    0.40
<EPS-DILUTED>                    0.40
        


</TABLE>
# CE2004070EN.01018201.xml

| 20.3.2004 | EN | Official Journal of the European Union | CE 70/182 |
| --- | --- | --- | --- |

20.3.2004

EN

Official Journal of the European Union

CE 70/182

---

(2004/C 70 E/191)

WRITTEN QUESTION P-2976/03

by Heinz Kindermann (PSE) to the Commission

(6 October 2003)

Subject:   Export refunds for ovalbumin — my question P-2696/03

Subject:

My question P-2696/03 (1) raised two issues concerning export refunds for ovalbumin. In its answer, the Commission addressed the first of these but not the second more important aspect.

1

In addition to the assessment of the effects on the ovalbumin sector of the measures decided, provided in the answer, I should appreciate a reply to the following questions:

| — | Is the Commission prepared to change the tariff classification of ovalbumin by reclassifying it under agricultural products, thus placing it on the same footing as other egg products such as eggs in shell, egg yolk and whole egg (CN Code 0408)? |
| --- | --- |

—

Is the Commission prepared to change the tariff classification of ovalbumin by reclassifying it under agricultural products, thus placing it on the same footing as other egg products such as eggs in shell, egg yolk and whole egg (CN Code 0408)?

| — | If so, what timescale does it have in mind? If not, why not? |
| --- | --- |

—

If so, what timescale does it have in mind? If not, why not?

Answer given by Mr Fischler on behalf of the Commission

(12 November 2003)

(12 November 2003)

The Commission considers that a change in the tariff classification of ovalbumin from CN Code 3502 to CN Code 0408 by the Community alone would not be possible, as the present classification is based on the Harmonized System Convention.

Moreover, the possibility to take up ovalbumin as a product covered by the common organisation of market in the eggs sector could possibly be envisaged, but the Community could not grant any refunds under its World Trade Organisation (WTO) commitment on eggs, because the position 35 02 ovalbumin is not in the Annex to the EC-WTO export subsidies commitments under this product group.

---

(1)  See page 129.

1

---